Pharmeral

Pharmeral is a preclinical-stage biotechnology company focused on developing next-generation long-acting protein therapeutics for metabolic diseases. Founded by former Amgen scientists, the company leverages a proprietary platform to enhance the pharmacokinetic profiles of biologics, specifically targeting the Fibroblast Growth Factor 21 (FGF21) pathway. Their lead programs aim to treat metabolic dysfunction-associated steatohepatitis (MASH) and obesity by providing potent, sustained-release treatments that improve patient compliance and efficacy. Pharmeral operates out of Thousand Oaks, California, and maintains a research presence in Suzhou, China. The company's approach combines deep expertise in protein engineering with innovative drug delivery technologies to address significant unmet needs in chronic metabolic conditions.